Related Experiment Video
Updated: Apr 22, 2026
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Diabetes treatment in patients with renal disease: Is the landscape clear enough?
1Ioannis Ioannidis, 2 Department of Internal Medicine, Konstantopoulio Hospital, Nea Ionia, 14233 Athens, Greece.
Insights
Managing diabetes and chronic kidney disease (CKD) requires careful medication choices. Metformin is a preferred first-line treatment for diabetic CKD patients with eGFR above 30 mL/min/1.73m², with careful monitoring and dose adjustment needed for others.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Diabetes mellitus is a primary risk factor for chronic kidney disease (CKD), with rising global incidence.
- Diabetic CKD patients require complex management of metabolic disorders and comorbidities like hypertension and cardiovascular disease.
- Limited safety and efficacy data for CKD patients in clinical trials create challenges in drug selection.
Purpose of the Study:
- To review the optimal management of hyperglycemia in diabetic patients with CKD.
- To evaluate the safety and efficacy of antidiabetic medications in patients with impaired renal function.
- To provide evidence-based recommendations for selecting antidiabetic drugs in the context of CKD.
Main Methods:
- Review of existing clinical guidelines and landmark studies, including UKPDS.
- Analysis of pharmacokinetic and pharmacodynamic data for various antidiabetic agents in renal impairment.
- Evaluation of adverse event profiles, particularly hypoglycemia and cardiovascular risks.
Main Results:
- Metformin is the preferred first-line agent for diabetic CKD patients with estimated Glomerular Filtration Rate (eGFR) > 30 mL/min/1.73m², offering low hypoglycemia risk and mortality benefits.
- Sulfonylureas, glinides, and insulin require cautious use with lower doses and slower titration due to increased hypoglycemia risk.
- Dipeptidyl peptidase-4 (DPP-4) inhibitors are effective and generally do not cause hypoglycemia, though dose adjustments may be needed for some.
Conclusions:
- Metformin remains the drug of choice for most diabetic CKD patients, with careful monitoring and dose adjustments based on eGFR.
- DPP-4 inhibitors offer a safer alternative to sulfonylureas and insulin for managing hyperglycemia in CKD.
- Individualized glycemic targets and thorough understanding of drug pharmacokinetics are crucial for safe and effective treatment of diabetic CKD.
Abstract:
Diabetes is the most important risk factors for chronic kidney disease (CKD). The risk of CKD attributable to diabetes continues to rise worldwide. Diabetic patients with CKD need complicated treatment for their metabolic disorders as well as for related comorbidities. They have to treat, often intensively, hypertension, dyslipidaemia, bone disease, anaemia, and frequently established cardiovascular disease. The treatment of hypoglycaemia in diabetic persons with CKD must tie their individual goals of glycaemia (usually less tight glycaemic control) and knowledge on the pharmacokinetics and pharmacodynamics of drugs available to a person with kidney disease. The problem is complicated from the fact that in many efficacy studies patients with CKD are excluded so data of safety and efficacy for these patients are missing. This results in fear of use by lack of evidence. Metformin is globally accepted as the first choice in practically all therapeutic algorithms for diabetic subjects. The advantages of metformin are low risk of hypoglycaemia, modest weight loss, effectiveness and low cost. Data of UKPDS indicate that treatment based on metformin results in less total as well cardiovascular mortality. Metformin remains the drug of choice for patients with diabetes and CKD provided that their estimate Glomerular Filtration Rate (eGFR) remains above 30 mL/min per square meter. For diabetic patients with eGFR between 30-60 mL/min per square meter more frequent monitoring of renal function and dose reduction of metformin is needed. The use of sulfonylureas, glinides and insulin carry a higher risk of hypoglycemia in these patients and must be very careful. Lower doses and slower titration of the dose is needed. Is better to avoid sulfonylureas with active hepatic metabolites, which are renally excreted. Very useful drugs for this group of patients emerge dipeptidyl peptidase 4 inhibitors. These drugs do not cause hypoglycemia and most of them (linagliptin is an exception) require dose reduction in various stages of renal disease.
More Related Videos
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
01:28Diabetic Nephropathy
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...